Drugs / DUSIGITUMAB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01498952 | Jan 2012 → Apr 2013 | hepatocellular carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01340040 | Jul 2011 → Apr 2012 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00816361 | Mar 2009 → Sep 2012 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01446159 | Jun 2011 → Jun 2019 | Her2-receptor negative breast cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DUSIGITUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109355 ↗ |
| Known as | MEDI-573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00816361 ↗ |
| Action | Inhibit | “Insulin-like growth factor II inhibitor” CHEMBL2109355 ↗2“Insulin-like growth factor I inhibitor” CHEMBL2109355 ↗ “a dual IGF-I/II neutralizing antibody” PMID 25342141 ↗ Oct 2014 |
| Modality | Monoclonal antibody | “a Fully Human Monoclonal Antibody” NCT00816361 ↗ |
| Route | Intravenous | “IV infusion” NCT00816361 ↗ |
| Target | IGF1 | “Insulin-like growth factor I inhibitor” CHEMBL2109355 ↗ |
| Target | IGF2 | “Insulin-like growth factor II inhibitor” CHEMBL2109355 ↗ |